Scope
AAO manages primary open-angle glaucoma by preserving useful vision over the patient’s lifetime through individualized intraocular-pressure reduction and repeated structural and visual-field assessment. Normal-range pressure does not exclude glaucoma or remove the benefit of treatment. The target pressure is an adjustable estimate, not a permanent threshold that guarantees stability.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Confirm open-angle optic neuropathy and establish a baseline
- Confirm an open angle on gonioscopy, characteristic optic-nerve or retinal nerve-fibre damage and compatible visual-field findings, while excluding secondary causes. Some patients have normal-range untreated pressure; lowering pressure remains beneficial in normal-tension glaucoma. [1]
- Obtain ocular and systemic history, family history of glaucoma-related visual loss, prior treatments and medicine intolerance. Include asthma or COPD, cardiovascular and blood-pressure disorders, sleep apnoea and current ocular or systemic medicines because these can influence treatment selection. [1]
- Assess acuity, pupils, slit-lamp findings, pressure, gonioscopy, optic nerve and retina. Prefer Goldmann applanation pressure measurement in each eye before gonioscopy or dilation. Base therapeutic decisions on several measurements when possible, rather than one reading. [1]
- Measure central corneal thickness to interpret pressure and risk. There is no generally accepted correction formula, and a numerical correction factor should not be used to convert an individual patient’s measured pressure into a presumed true value. [1]
- Use visual-field testing and optic-nerve/RNFL or macular OCT as complementary assessments. Tailor the field programme to the damage pattern; central testing can help when defects approach fixation. Repeat new or progressive defects with the same strategy and repeat unreliable tests after addressing artefacts. [1]
- Document the optic nerve and structural baseline with imaging or photographs where feasible; if unavailable, a drawing or non-stereoscopic photograph is a less desirable alternative. Structural change can precede a detectable visual-field change. [1]
Choose and reassess an individualized pressure target
- A reasonable initial goal in established POAG is pressure reduction of 20–30% below baseline, adjusted for severity and subsequent course. Select a lower target for more severe or rapidly progressing damage; consider treatment burden and life expectancy when balancing risks and benefits. [1]
- Reassess the target against optic-nerve imaging and visual fields over time. Progression despite achieving the current target is a reason to lower it further; pressure control alone is not proof that the optic nerve is protected. [1]
- Choose medication, laser or surgery with the patient, considering the degree of damage, efficacy, adverse effects, cost, practical adherence and preferences. Pregnancy, nursing, pulmonary disease and arrhythmia require specific consideration when selecting medicines. [1]
Select a feasible pressure-lowering treatment
- Laser trabeculoplasty can be initial or additional treatment for POAG. Selective laser trabeculoplasty has evidence supporting initial use; repeat SLT can be useful, whereas repeat argon treatment has lower effectiveness and greater pressure-spike risk. [1]
- For laser trabeculoplasty, check pressure immediately before treatment and within 30 minutes to 2 hours afterward. Arrange review within 6 weeks or sooner if optic-nerve damage from pressure is a concern. Use perioperative pressure-lowering medication when transient elevation is a concern. [1]
- Prostaglandin analogues are often the initial eye-drop choice because of efficacy, tolerability and once-daily dosing, unless contraindications, adverse effects, cost or patient preference favour another option. A topical medicine still needs assessment for systemic as well as ocular adverse effects. [1]
- Beta-blocker drops can affect cardiac and pulmonary receptors. Cardioselective agents reduce but do not abolish pulmonary adverse-effect risk in obstructive airway disease; do not assume that an eye drop is safe merely because it is locally administered. [1]
- Review drop dosage and frequency at each visit, and assess the ability to administer drops. Demonstrate technique and ask the patient or caregiver to demonstrate it; leave at least 5 minutes between different drops. Tailored education, written plans and reminders may help adherence. [1]
- If drops are impractical despite support, consider laser, sustained medication delivery or other surgery. Surgical choice depends on the pressure reduction needed and patient risk: traditional trabeculectomy or aqueous shunts generally lower pressure more than MIGS but carry greater complication risk. [1]
- MIGS generally gives more modest pressure reduction and a more favourable safety profile than traditional filtering surgery. Much of the trial evidence concerns mild-to-moderate open-angle glaucoma; procedures and device eligibility differ, including whether cataract surgery must be performed at the same time. [1]
Monitor progression, tolerability and daily function
- At follow-up, review interval eye and systemic history, medicine timing and adverse effects, and reassess acuity, slit-lamp findings and pressure. Repeat gonioscopy for suspected angle closure, shallowing, angle abnormalities or unexplained pressure change. [1]
- Choose review and testing intervals by damage severity, progression rate, target-pressure attainment and other risk factors. More severe or progressing disease, uncertain tests and a need to establish a reliable baseline justify more frequent assessments; the routine calendar must not override clinical deterioration. [1]
- Adjust therapy if target pressure is not met, damage progresses, treatment is intolerable, adherence is not feasible or a contraindication develops. In a patient stable for a prolonged period, a carefully monitored reduction in drops may be reasonable. After changing treatment, a 2–8-week review may help assess efficacy and adverse effects, depending on severity. [1]
- Explain the disease and treatment goals, check understanding, and address fear of blindness or barriers to care. Seek a glaucoma specialist when diagnosis or management is uncertain or treatment is ineffective. Offer vision rehabilitation, fall-risk support and counselling when functional loss affects daily life. [1]
Limitations and use
- This summary concerns established adult primary open-angle glaucoma. It is not an acute angle-closure pathway or the separate assessment pathway for glaucoma suspects.
- It summarizes diagnostic, treatment-selection and follow-up principles; it does not reproduce the full medicine contraindication table, device-specific instructions, surgical technique, perioperative protocols or every severity-specific surveillance interval.
- A target pressure and percentage reduction are starting estimates, not validated guarantees of safety. Structural and functional progression, adherence and the patient’s remaining useful vision must guide continuing decisions.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Primary open-angle glaucoma
Selected recommendation material consulted
Publication details
- Issuing organisation
- AAO
- First published
- 9 February 2026
- Resource type
- Preferred Practice Pattern guideline · House clinical summary
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.